Learn more about our Legal work.
The case arises from Gilead Sciences’ successful HIV/AIDS drug, tenofovir disoproxil fumarate (TDF). Plaintiffs allege injury from TDF but do not allege any defect with the design, manufacture, marketing, or…
Third party litigation funding has become widespread in the civil justice system. The growing use of TPLF to generate mass tort litigation, particularly against manufacturers of medical technology, misuses the…
Although the individual claims may differ, a review of recent products liability claims levied against industries targeted by the plaintiffs trial bar reveals common threads. For example, the drivers of…
Relator was contending that commission-based contract sales arrangements are per se violations of the AKS. AdvaMed® noted that this suit is the first time a plaintiff has alleged that a…
On September 13th, 2023, the U.S. House Oversight Committee held a hearing on the impact of third-party litigation financing, an issue of significant concern to AdvaMed® and its members. Third-party…
Today, AdvaMed®, the Medtech Association, submitted a letter to the House Committee on Oversight and Accountability regarding the Committee’s consideration of an issue that threatens to undermine the foundations of…
Register for the 16th Annual King & Spalding Medical Device Summit in Chicago!
AdvaMed® submits amicus briefs on a variety of topics because of the strong interest and relevance to the medtech industry.
The case involved expansive Biometric Privacy Act (BIPA) liability for medical device manufacturers. The device at issue was a medstation manufactured by BD that stores patient pharmaceuticals that can be…
Chris White, AdvaMed®’s General Counsel, explores the GAO’s recent report as “a welcome independent review raising attention to the need for disclosure and regulation of the litigation financing that fuels…